logo-loader
RNS
viewArix Bioscience PLC

Arix Bioscience Plc - Holding(s) in Company

TR-1: Standard form for notification of major holdings

   

   

   

   

   

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the
 in Microsoft Word format if possible)i

1a. Identity of the issuer or the       Arix Bioscience Plc
underlying issuer of existing shares to
which voting rights are attachedii:

1b. Please indicate if the issuer is a non- issuer (please mark with an “X”
if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with
an “X”)

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:                                                    X
No trading in the stock - voting control interest over stock transferred to
new manager

3. Details of person subject to the notification obligationiv

Name                                    Woodford Investment Management Ltd

City and country of registered office   9400 Garsington Road, Oxford, OX4 2HN,
(if applicable)                         United Kingdom

4. Full name of shareholder(s) (if different from 3.)v



City and country of registered office
(if applicable)

5. Date on which the threshold was      05/07/2019
crossed or reachedvi:

6. Date on which issuer notified        08/07/2019
(DD/MM/YYYY):

7. Total positions of person(s) subject to the notification obligation

                    % of voting rights % of voting rights Total of both in % Tot
                    attached to shares through financial  (8.A + 8.B)        al
                    (total of 8. A)    instruments                           num
                                       (total of 8.B 1 +                     ber
                                       8.B 2)                                of
                                                                             vot
                                                                             ing
                                                                             rig
                                                                             hts
                                                                             of
                                                                             iss
                                                                             uer
                                                                             vii

Resulting situation 19.78%                                19.78%             135
on the date on                                                               ,55
which threshold was                                                          1,8
crossed or reached                                                           50

Position of         21.89%                                21.89%
previous
notification (if
applicable)FCANameUK
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of Number of voting rightsix        % of voting rights
shares
ISIN code (if Direct              Indirect     Direct              Indirect
possible)     (Art 9 of Directive (Art 10 of   (Art 9 of Directive (Art 10 of
              2004/109/EC)        Directive    2004/109/EC)        Directive
              (DTR5.1)            2004/109/EC) (DTR5.1)            2004/109/EC)
                                  (DTR5.2.1)                       (DTR5.2.1)

GB00BD045071  26,819,617                       19.78%

SUBTOTAL 8. A 26,819,617                       19.78%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive
2004/109/EC (DTR5.3.1.1 (a))

Type of financial Expiration Exercise/       Number of voting     % of voting
instrument        datex      Conversion      rights that may be   rights
                             Periodxi        acquired if the
                                             instrument is
                                             exercised/converted.

                             SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13
(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of    Expiration Exercise/  Physical or cash Number of voting % of voting
financial  datex      Conversion                  rights           rights
instrument            Period xi  settlementxii

                                 SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural X
person or legal entity and does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entityxiv (please add additional rows as
necessary)

Namexv              % of voting rights if it     % of voting rights through   Tot
                    equals or is higher than the financial instruments if it  al
                    notifiable threshold         equals or is higher than the of
                                                 notifiable threshold         bot
                                                                              h
                                                                              if
                                                                              it
                                                                              equ
                                                                              als
                                                                              or
                                                                              is
                                                                              hig
                                                                              her
                                                                              tha
                                                                              n
                                                                              the
                                                                              not
                                                                              ifi
                                                                              abl
                                                                              e
                                                                              thr
                                                                              esh
                                                                              old

Woodford Investment 19.78                        0.00                         19.
Management Ltd                                                                78

10. In case of proxy voting, please identify:

 of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be
held

11. Additional informationxviName
Place of completion , Oxford, OX4 2HN, 

Date of completion9400 Garsington RoadUnited Kingdom08/07/2019

Quick facts: Arix Bioscience PLC

Price: 78.5

Market: LSE
Market Cap: £106.45 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018